Navigation Links
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Date:3/31/2008

- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V -

CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out to two years, including an observed 40 percent reduction in major adverse cardiac events (MACE) and an observed 44 percent reduction in vessel retreatment (ischemia-driven target lesion revascularization, TLR) compared to the TAXUS(R) paclitaxel-eluting coronary stent system. The two-year results from the SPIRIT II trial were presented at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit.

SPIRIT II is a 300-patient randomized clinical trial, which was conducted in Europe and Asia Pacific to support the launch of XIENCE V outside the United States. In SPIRIT II, XIENCE V demonstrated the following key results:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated an observed 40 percent reduction in MACE compared to

TAXUS at two years (6.6 percent for XIENCE V vs. 11.0 percent for

TAXUS). MACE is an important clinical measure of patient outcomes,

defined as cardiac death, heart attack (myocardial infarction or MI),

or ischemia-driven target lesion revascularization.

-- XIENCE V demonstrated an observed 44 percent reduction in

ischemia-driven target lesion revascularization (TLR driven by lack of

blood supply) compared to TAXUS at two years (3.8 percent for XIENCE V

vs. 6.8 percent for TAXUS).

-- Rates of definite/probable stent thrombosis under the Dublin/Academic

Research Consortium (ARC) definition were 0.9 percent for XIENCE V and

1.4 percent for TAXUS at two years. The ARC definition of late-stent

thrombosis was developed to eliminate variability in the definitions

across various drug eluting stent trials.

"In clinical endpoints such as major adverse cardiac events, retreatment and heart attack, patients treated with XIENCE V in the SPIRIT II clinical trial continue to fare better than patients treated with TAXUS out to two years," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the SPIRIT II clinical trial, who presented the results today. "XIENCE V is performing as we would expect a next-generation drug eluting stent should over the long term, specifically on the important clinical endpoint of MACE. The low rate of MACE with XIENCE V compared to TAXUS was present at 6 months, one year and now at two years in the SPIRIT II trial."

In a small subset of patients in the SPIRIT II trial, in-stent imaging results were evaluated at two years. In this 117-patient subset, the angiographic in-stent late loss rate was 0.33 mm for XIENCE V and 0.34 mm for TAXUS at two years. In-stent late loss is a measure of vessel renarrowing within the margins of the stent.

"At any given point in time, across both the pivotal SPIRIT II and SPIRIT III clinical trials, XIENCE V consistently reduces observed MACE rates by 40 percent or more compared to TAXUS," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "The single-digit MACE rate seen with XIENCE V out to two years is encouraging data for interventionalists as they look for ways to improve patient outcomes with next-generation drug eluting stents."

XIENCE V was launched in Europe and other international markets in late 2006. XIENCE V is an investigational device in the United States and Japan, and is currently under review for approval by the U.S. Food and Drug Administration.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies.

Everolimus is licensed to Abbott by Novartis for use on its drug eluting stents.

For images of Abbott's XIENCE V stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 68,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
4. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
5. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)...  The China and Canada joint tech ... water, energy and detergent, and features a powerful disinfection process. ... washing machine that washes and sanitizes women,s panties or babies, cloth ... ... does not require an external water inlet. ...
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... 24, 2017 , ... In modern research, success depends greatly ... for research and understanding the basic principles that were designed to drive that ... in stereo microscopy for brightfield and fluorescence typically used in laboratories working on ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Altec ... its participation in nVerge 2017 – a one-day technology conference in San Diego, CA. ... management solution, which allows users to fully utilize and enhance their Sage ERP solutions ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and ... now spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation ... Through the program, private practitioners receive cutting-edge clinical training and learn how to ...
(Date:5/24/2017)... OH (PRWEB) , ... May 24, 2017 , ... Patients ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, with ... while simultaneously improving their oral health and functionality. , Dr. Bedich offers ...
Breaking Medicine News(10 mins):